The first nasal spray medication for treatment-resistant depression.
SPRAVATO® is a prescription medicine, used along with an antidepressant taken by mouth to treat Depressive symptoms in adults with major depressive disorder (MDD) and Treatment-resistant depression (TRD).
About SPRAVATO®
If you’re struggling with your depression or just don’t feel like your medication is working…don’t lose hope! SPRAVATO® (esketamine) is the first and only NMDA receptor antagonist approved for 2 subtypes of MDD in adult patients:
- Treatment-resistant depression (TRD)
Major depressive disorder (MDD)
If you’ve struggling with depressive symptoms after trying two or more antidepressants, talk to your doctor to see if you may have treatment-resistant depression.
SPRAVATO® is:
- Easy-to-use: Nasal spray you self-administer under the supervision of a healthcare provider
- Innovative: SPRAVATO® targets the N-methyl-D-aspartate (NMDA) receptor and is believed to work differently than currently available oral antidepressants.
- Safe: a healthcare provider will monitor you for at least two hours during the observation period to ensure safety throughout treatment